The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among ...
Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with ...
Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more ...
Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company ...
In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of four peptides despite a ...
Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a ...
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...
While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to ...
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British ...
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future ...
A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck ...
The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results